Best deal of the week
DR. DOPING

Instructions

Logo DR. DOPING

Instruction for use: Viferon

I want this, give me price

Dosage form: Gel for local and external use; Ointment for local and external use; Rectal suppositories

Active substance: Interferonum alpha-2b

ATX

L03AB01 Interferon alfa

Pharmacological groups:

Cytokine [Antiviral (except HIV) agents]

Cytokine [Interferons]

The nosological classification (ICD-10)

A08.4 Viral intestinal infection, unspecified: Viral diarrhea; Enterovirus infection

A41.9 Septicemia, unspecified: Septic diseases; Septicemia / bacteremia; Toxico-infectious shock; Endotoxin shock; Bacterial septicemia; Bacterial infections of severe course; Generalized infections; Generalized systemic infections; Infections generalized; Wound sepsis; Septiccopymia; Septic-toxic complications; Septicemia; Septic conditions; Septic shock; Septic condition; Septic shock

A49 Bacterial infection of unspecified site: Bacterial infection; Infectious diseases

A49.3 Mycoplasma infection, unspecified: Mycoplasma infection; Urogenital mycoplasmosis; Pulmonary infection caused by mycoplasma; Mycoplasma infections; Mycoplasmosis; Genitourinary infection caused by mycoplasma; Mycoplasma meningoencephalitis

A56 Other chlamydial diseases, sexually transmitted infections: Chlamydial infections; Chlamydia; Tropical bubo

A59.0 Urogenital Trichomoniasis: Trichomonas Colpitis; Trichomonas infection of the urinary tract; Vaginal trichomoniasis; Trichomonal vaginitis; Trichomonas inflammation of the vagina; Trichomonas inflammation of the urinary tract; Trichomonas vaginitis; Trichomonal Urethritis; Trichomonatal balanoposthitis; Trichomonas vulvovaginitis; Trichomonal Urethritis; Urethritis caused by Trichomonas; Trichomonas urethritis; Vaginitis due to Trichomonas; Trichomoniasis of the genitourinary system; Trichomonas colpitis; Trichomonas infection of the urogenital organs

A60 Anogenital herpetic viral infection [herpes simplex]: Herpes simplex genitalis; Banal recurrent genital herpes; Secondary genital herpes; Genital herpesvirus infection; Genital herpetic infections; Genital herpes; Herpes genitalia; Genital herpes; Herpes simplex organs; Herpetic lesions of the mucocutaneous urinary organs; Herpetic lesions of the genitals; Primary genital herpes; Primary herpes simplex; Simple herpes extragenital and genital localization; Recurrent genital herpes; Recurrent herpes of genital organs; Herpes of the lips and genitals

A63.8 Other specified diseases, mainly sexually transmitted: Ureaplasmosis infection; Ureaplasmic infection; Ureaplasmosis

A74.8 Other chlamydial diseases: Respiratory chlamydia; Chlamydial pneumonia; Chlamydial pneumonia

A74.9 Chlamydial infection, unspecified: Chlamydial infections; Uncomplicated chlamydia; Chlamydiasis; Chlamydial infection; Chlamydial infections; Extragenital chlamydia; Chlamydia

A87 Viral meningitis

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B00.0 Herpetic Eczema: Herpes Skin; Herpes on the skin; Eczema herpetiform Kaposi; Acute herpetic skin disease; Primary herpetic infection of the skin and mucous membranes; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Herpetic infection of the skin; Herpetic lesions of the skin; Herpetic dermatitis; Herpetic lesions of the skin; Herpetic lesions of the skin and mucous membranes; Recurrent herpetic infection of the skin; Simple skin herpes; Herpes-viral infections; Herpetic infection; Herpetic infections; Herpetic lesions; Latent herpetic infection; Neonatal herpes; Recurrent herpetic infection; Chronic recurrent herpesvirus infection; Chronic recurrent herpetic infection

B00.1 Herpetic vesicular dermatitis: Herpetic vesicular dermatitis of the lips; Bubbling herpetic dermatitis; Herpes

B00.8 Other forms of herpetic infections: Herpes labialis Solaris; Herpes labialis; Herpes lips; Labial herpes; Urogenital herpetic infection

B16 Acute hepatitis B: Viral hepatitis B; Hepatitis B; Acute hepatitis; Vaccination against hepatitis B; Subacute hepatitis; Acute viral hepatitis B; Acute lingering hepatitis B

B17.1 Acute hepatitis C: Viral active hepatitis C; Viral hepatitis C; Hepatitis C

B18 Chronic viral hepatitis

B18.8 Other chronic viral hepatitis: Chronic active hepatitis D; Chronic hepatitis Delta; Chronic hepatitis A; Chronic viral hepatitis D

B19 Viral hepatitis, unspecified: Anemia without hepatitis; Viral hepatitis; Viral hepatitis in children; Infection of the liver; Acute liver infection

B25.9 Cytomegalovirus disease, unspecified: CMV; CMV infection; Cytomegalovirus infection

B34 Viral infection of unspecified site: Viral respiratory tract infections; Infections viral; Viral infection; Viral infections

B37 Candidiasis: Visceral candidiasis; Invasive Candidiasis; Candidiasis of the larynx; Candidiasis of the digestive tract; Candidiasis of the skin and mucous membranes; Candidiasis of mucous membranes and skin; Candidiasis of the mucous membranes; Candidiasis due to Candida albicans; Candidomycosis; Acute pseudomembranous candidiasis; Chronic forms of candidiasis

B37.3 Candidiasis of the vulva and vagina (N77.1 *): Vaginal candidiasis; Vaginal candidiasis; Vulval candidiasis; Vulvovaginal candidiasis; Vulvovaginal candidiasis; Vulvovaginitis candidiasis; Mycotic vulvovaginitis; Fungal vaginitis; Candidiasis of the vagina; Candidiasis of internal organs; Candidiasis of the urogenital; Candidiasis of the urogenital organs in women; Candidiasis with lesions of the skin and mucous membranes; Candidiasis of the mucous membranes; Candidiasis of mucous membranes and skin; Candidiasis of the vaginitis; Candidiasis vulvitis; Candidiasis vulvovaginitis; Colpitis of fungal etiology; Vaginal yeast infection; Moniliasis vulvovaginitis; Acute vaginal candidiasis; Acute mycosis of the vagina; Superficial candidiasis of the genital mucosa; Recurrent vaginal candidiasis; Recurrent vaginal candidiasis; Urogenital Candidiasis; Chronic vaginal candidiasis; Chronic candidiasis of mucous membranes; Chronic recurrent vaginal candidiasis

B97.7 Papillomavirus: Human papillomavirus; Asymptomatic selection of human papillomavirus; Papillomavirus infection; The papilloma virus; Upper respiratory tract papillomatosis; Papillomovirus infection; Human papillomaviruses

G00 Bacterial meningitis, not elsewhere classified: Meningitis; Meningeal infections; Meningitis of bacterial etiology; Pachymeningitis external; Epiduritis purulent

G03.9 Meningitis, unspecified: Arachnoiditis; Consequence of meningitis; Serous meningitis; Cerebral meningitis; Meningitis subacute

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J11 Influenza, virus not identified: Influenza; Influenza in the early stages of the disease; Influenza in children; cold in the chest; Begins flu-like condition; Acute disease parainfluenza; parainfluenza; parainfluenza state; influenza epidemics; The pains of the influenza

J12.9 Viral pneumonia, unspecified: Pneumonia viral

J16.0 Pneumonia caused by chlamydia: Primary atypical pneumonia; Pneumonia Illinois; Pneumonia of Louisiana; Chlamydial pneumonia; Chlamydial pneumonia; Pneumonia primary atypical

J18 Pneumonia without specification of pathogens: Alveolar pneumonia; Community-acquired pneumonia atypical; Community-acquired pneumonia non-pneumococcal; Pneumonia; Inflammation of the lower respiratory tract; Inflammatory lung disease; Shared pneumonia; Respiratory and lung infections; Infections of the lower respiratory tract; Cough with inflammatory diseases of the lungs and bronchi; Croupous pneumonia; Nosocomial pneumonia; Exacerbation of chronic pneumonia; Acute community-acquired pneumonia; Acute pneumonia; Focal pneumonia; Pneumonia abscessing; Pneumonia bacterial; Pneumonia croupy; Pneumonia of focal; Pneumonia with difficulty in sputum discharge; Pneumonia in AIDS patients; Pneumonia in children; Septic pneumonia; Chronic Obstructive Pneumonia; Chronic pneumonia; Lymphoid interstitial pneumonia

K74 Fibrosis and cirrhosis of the liver: Edematous-ascitic syndrome in cirrhosis; Inflammatory liver disease; Pretsirroticheskoe state; Cystic fibrosis of the liver; Cirrhotic and pretsirroticheskoe state; Cirrhosis portal hypertension c; Cirrhosis of the liver with signs of portal hypertension; Cirrhosis of the liver with portal hypertension and edema-ascites syndrome; Cirrhosis of the liver with portal hypertension; Liver cirrhosis with ascites and edema; Liver cirrhosis with ascites; cirrhotic ascites

N39.0 Urinary tract infection without established localization: Fungal infections of the urinary tract; Asymptomatic bacteriuria; Bacterial infections of the urinary tract; Bacterial infections of the urinary tract; Bacterial infections of the genitourinary system; Bacteriuria; Bacteriuria asymptomatic; Bacteriuria chronic latent; Asymptomatic bacteriuria; Asymptomatic massive bacteriuria; Inflammatory urinary tract disease; Inflammatory urinary tract disease; Inflammatory diseases of the bladder and urinary tract; Inflammatory diseases of the urinary system; Inflammatory diseases of the urinary tract; Inflammatory diseases of the urogenital system; Fungal diseases of the urogenital tract; Urinary Tract Infections; Urinary Tract Infections; Infections of the urinary system; Urinary tract infections; Urinary Tract Infections; Urinary tract infections caused by enterococci or mixed flora; Urinary tract infections uncomplicated; Urinary tract infections complicated; Infections of the urogenital system; Infections urogenital; Infectious diseases of the urinary tract; Urinary Tract Infection; Urinary tract infection; Urinary system infection; Urinary tract infection; Urinary tract infection; Infection of the urogenital tract; Uncomplicated urinary tract infections; Uncomplicated urinary tract infections; Uncomplicated urinary tract infections; Uncomplicated infections of the genitourinary system; Exacerbation of chronic urinary tract infection; Retrograde kidney infection; Recurrent urinary tract infections; Recurrent urinary tract infections; Recurrent infectious diseases of the urinary tract; Mixed urethral infections; Urogenital infection; Urogenital Infectious-Inflammatory Disease; Urogenital mycoplasmosis; Urologic disease of infectious etiology; Chronic urinary tract infection; Chronic inflammatory diseases of the pelvic organs; Chronic urinary tract infections; Chronic infectious diseases of the urinary system

N49 Inflammatory diseases of male genital organs, not elsewhere classified: Bacterial diseases of urogenital tract; Bacterial infections of the genitourinary system; Sexually Transmitted Infections in Men; Infections urogenital; Infectious diseases of the reproductive system; Infectious diseases of genital organs; Chronic inflammatory diseases of the pelvic organs; Infections of the male genital tract

N76 Other inflammatory diseases of the vagina and vulva: Vulvovaginitis atrophic; Vulvovaginitis bacterial; Vulvovaginitis estrogen-deficient; Bacterial vaginosis; Vaginitis; Vaginitis bacterial; Inflammatory diseases of the vagina and vulva; Inflammatory diseases of female genitalia; Inflammatory diseases of female genital organs; Vulvit; Vulvovaginitis; Vulvovaginitis; Gardnerella; Fungal vulvovaginitis in girls and virgins; Infection of the vagina; Infection of the genitals; Colpitis; Violation of purity of the vaginal secretion; Nonspecific cervicovaginitis; Nonspecific vulvitis; Nonspecific vulvovaginitis; Nonspecific colpitis; Recurrent nonspecific bacterial vaginosis; Senylic coverings; Mixed Colpus; Chronic vaginitis; Vulvovaginal infections; Bacterial vaginitis; Bacterial vaginosis; Bacterial vaginitis; Mixed vaginal infections

O35.3 Fetal infection (presumed) as a result of a mother's viral illness, requiring the provision of medical assistance to the mother

O35.8 Other fetal abnormalities and lesions (presumed) requiring maternal care

Composition

Ointment for topical and topical application 1 g

active substance: Interferon human recombinant alpha-2 40000 IU

Auxiliary substances: tocopherol acetate - 0.02 g; Lanolin anhydrous - 0.34 g; Vaseline medical - 0.45 g; Peach oil - 0.12 g; Purified water - up to 1 g

Gel for topical and topical use 1 g

active substance: Interferon human recombinant alpha-2b 36,000 IU

Auxiliary substances: alpha-tocopherol acetate - 0.055 g; Methionine - 0.0012 g; Benzoic acid 0.00128 mg; Citric acid monohydrate 0.001 g; Sodium tetraborate decahydrate - 0.0018 mg; Sodium chloride - 0.004 g; Albumin serum human solution 10% - 0.02 g; Glycerin distilled (glycerol) - 0.02 g; Carmellose sodium - 0.02 g; Ethanol 95% - 0.055 g; Purified water - up to 1 g

Suppositories for rectal administration 1 supp.

active substance: Interferon human recombinant alpha-2b 150000 IU; 500,000 IU; 1,000,000 IU; 3000000 IU

Auxiliary substances: alpha-tocopherol acetate - 0.055 / 0.055 / 0.055 / 0.055 g; Ascorbic acid - 0.0054 / 0.0081 / 0.0081 / 0.0081 g; Sodium ascorbate - 0.0108 / 0.0162 / 0.0162 / 0.0162 g; Disodium edetate dihydrate 0.0001 / 0.0001 / 0.0001 / 0.0001 g; Polysorbate 80 - 0.0001 / 0.0001 / 0.0001 / 0.0001 g

Base: cocoa butter and confectionery fat - up to 1 g

Description of dosage form

Ointment: yellow or yellowish white, viscous, homogeneous, with a specific smell of lanolin.

Gel: homogeneous, opaque, gel-like mass of white with a grayish shade of color.

Suppositories: bullet-shaped, white with a yellowish tinge, homogeneous consistency. Color heterogeneity in the form of marble is allowed. On the longitudinal section there is a funnel-shaped depression. The diameter of the suppository is no more than 10 mm.

Pharmachologic effect

Mode of action - antiviral, immunomodulating, antiproliferative.

Pharmacodynamics

Interferon alfa-2b human recombinant has pronounced immunomodulatory, antiviral, antiproliferative properties, inhibits the replication of RNA and DNA-containing viruses.

The complex composition of the preparations (ointment, suppository, gel) causes a number of new additional effects: in the presence of antioxidants (tocopherol acetate and / or ascorbic acid), the specific antiviral activity of human interferon recombinant alpha-2b increases, its immunomodulating effect on T- and B-lymphocytes , The level of secretory immunoglobulins class A increases, the level of immunoglobulin E normalizes, and the endogenous system of interferon alfa-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and regenerative properties. The use of the preparation VIFERON® as part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as to reduce the toxic effects of this therapy.

It was found that when using the preparation VIFERON® there are no side effects arising from the parenteral administration of interferon alfa-2b preparations, antibodies that neutralize the antiviral activity of interferon alfa-2b are not formed

Indication of the Viferon

Ointment

Viral (including herpetic) lesions of the skin and mucous membranes of different locations;

Treatment of influenza and ARVI in children aged 1 year.

Gel

In the complex therapy of acute respiratory viral infections, incl. Influenza, frequent and prolonged ARVI, incl. Complicated by a bacterial infection;

Prevention of ARVI, including influenza;

In the complex therapy of recurrent stenosing laryngotraheobronchitis;

Prevention of recurrent stenosing laryngotraheobronchitis;

In the complex therapy of acute and exacerbations of chronic recurrent herpetic infection of the skin and mucous membranes, incl. Urogenital form of herpetic infection;

In the complex therapy of herpetic cervicitis.

Suppositories

In complex therapy:

ARVI, including influenza, incl. Complicated with bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults;

Infectious and inflammatory diseases of newborn children, incl. Premature: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, CMV infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis);

Chronic viral hepatitis B, C, D in children and adults, incl. In combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of severe activity complicated by cirrhosis of the liver;

Infectious and inflammatory diseases of the urogenital tract (chlamydia, CMV infection, ureaplasmosis, trichomoniasis, gardnerellez, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults;

Primary or recurrent herpetic infection of skin and mucous membranes, localized form, mild and moderate-to-moderate course, incl. Urogenital form in adults.

Contraindications

Ointment: individual intolerance to the components of the drug.

Gel: hypersensitivity to any of the components of the drug.

Suppositories: hypersensitivity to any of the components of the drug.

Application in pregnancy and breastfeeding

Ointment: since external and local administration of interferon systemic absorption is low and the drug has an effect only in the lesion, it is possible to use the preparation VIFERON® during pregnancy and lactation.

Gel: since the local absorption of interferon is low and the drug has an effect only in the lesion, it is possible to use the preparation VIFERON® during pregnancy and breastfeeding. During lactation, do not apply the drug to the nipple and areola areas.

Suppositories: the drug is approved for use with the 14th week of pregnancy. Has no limitations to use during lactation.

Side effects

Ointment: In most cases, the preparation of VFERHERON® is well tolerated. When applied to the nasal mucosa, side effects are of a mild and transitory nature, disappear on their own after the drug is discontinued.

Gel: in extremely rare cases, a local allergic reaction may occur in certain highly sensitive individuals. In such cases, the drug is discontinued.

Suppositories: in rare cases - allergic reactions (skin rashes, itching). These phenomena are reversible and disappear after 72 hours after discontinuation of the drug.

Interaction

Preparations VIFERON® (ointment, gel and suppositories) are compatible and well combined with all medicines used in the treatment of viral and other diseases (antibiotics, chemotherapeutics, GCS).

Dosing and Administration

Ointment, externally and topically. When herpetic infection ointment is applied a thin layer on the lesions 3-4 times a day and gently rub. Duration of treatment is 5-7 days. It is recommended to start treatment immediately after the appearance of the first signs of skin and mucous membrane lesions (itching, burning, redness). When treating relapsing herpes it is desirable to begin treatment in the prodromal period or at the very beginning of the appearance of signs of relapse.

To treat influenza and other SARS, ointment is applied a thin layer on the mucous membrane of the nasal passages 3-4 times a day the entire period of the disease.

Children from 1 year to 2 years - 2500 IU (1 pea 0.5 cm in diameter) 3 times a day; From 2 to 12 years - 2500 IU (1 pea 0.5 cm in diameter) 4 times a day; From 12 to 18 years - 5000 IU (1 pea with a diameter of 1 cm) 4 times a day. Duration of treatment is 5 days.

Gel, externally and topically.

In the complex therapy of acute respiratory viral infection, including influenza, prolonged and frequent ARI, incl. Complicated by bacterial infection: a strip of gel with a length of no more than 0.5 cm is applied to the previously dried surface of the nasal mucosa and / or to the surface of the palatine tonsils 3-5 times a day with a spatula or cotton swab / cotton swab (see Note). The course of treatment is 5 days, if necessary, the course can be extended.

Prevention of acute respiratory viral infection, including influenza: during the period of incidence of the incidence, a strip of gel not more than 0.5 cm long is applied to the previously dried surface of the nasal mucosa and / or to the surface of the palatine tonsils 2 times a day for 2-4 weeks.

In complex therapy of recurrent stenosing laryngotrahebronchitis: a strip of gel with a length of no more than 0.5 cm is applied to the surface of the tonsils using a spatula or cotton swab / cotton swab in the acute period of the disease 5 times a day, for 5-7 days, then 3 times in Day for the next 3 weeks.

Prevention of recurrent stenosing laryngotraheobronchitis: a strip of gel with a length of no more than 0.5 cm is applied to the surface of the palatine tonsils with a spatula or cotton swab / cotton swab twice a day for 3-4 weeks, the courses are repeated 2 times a year.

In the complex therapy of acute and chronic recurrent herpetic infection (with the appearance of the first signs of the disease or during the precursors): a strip of gel with a length of no more than 0.5 cm is applied with a spatula or cotton swab / cotton swab on the pre-dried affected surface 3-5 times in Day for 5-6 days, if necessary, the duration of the course is increased until the disappearance of clinical manifestations.

In the complex therapy of herpetic cervicitis: 1 ml of the gel is applied with a cotton swab on the pre-cleaned surface of the cervix 2 times a day for 7 days, if necessary, the duration of the course can be increased to 14 days.

Note. On the mucous membrane of the nasal cavity, the gel is applied after cleansing the nasal passages, on the surface of the tonsils - 30 minutes after eating. When applying the gel to the palatine tonsils do not touch the tonsils with a cotton swab, but only gel, while the gel itself flows down the surface of the amygdala. When applying the gel to the cervix, you should first remove the mucus and gauze swab from the vagina and the cervix.

When applying the gel to the affected skin and mucous membranes after 30-40 minutes a thin film is formed, on which the drug is again applied. If desired, the film can be peeled off or washed off with water before re-applying the preparation.

Suppositories, rectally.

1 suppository contains, as active substance, human recombinant interferon alpha-2b at indicated dosages (150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU).

Acute respiratory viral infections, including influenza, incl. Complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy. Recommended dose for adults, including pregnant women and children over 7 years of age, VFERHORON® 500,000 IU per 1 suppository 2 times a day after 12 hours daily for 5 days. According to clinical indications, therapy can be continued.

Children under 7 years, incl. Newborn and premature with a gestational age of more than 34 weeks recommended the use of the drug VIFERON® 150000 IU for 1 suppository 2 times a day after 12 hours daily for 5 days. According to clinical indications, therapy can be continued. The break between the courses is 5 days.

Preterm infants with gestational age less than 34 weeks are recommended to use the preparation VIFERON® 150000 IU for 1 suppository 3 times a day after 8 hours daily for 5 days. According to clinical indications, therapy can be continued. The break between the courses is 5 days.

Infectious and inflammatory diseases of newborn children, incl. Premature: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, CMV infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy. Recommended dose for newborns, incl. Premature with a gestational age of more than 34 weeks VIFERON® 150,000 IU daily for 1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.

Preterm infants with gestational age less than 34 weeks are recommended to use VIFERON® 150,000 IU daily for 1 suppository 3 times a day after 8 hours. The course of treatment is 5 days.

The recommended number of courses for various infectious and inflammatory diseases: sepsis - 2-3 courses, meningitis - 1-2 courses, herpetic infection - 2 courses, enterovirus infection - 1-2 courses, CMV infection - 2-3 courses, mycoplasmosis, candidiasis , In tch visceral - 2-3 courses. The break between the courses is 5 days. According to clinical indications, therapy can be continued.

Chronic viral hepatitis B, C, D in children and adults as part of complex therapy, incl. In combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of severe activity complicated by cirrhosis of the liver. The recommended dose for adults is VIFERON® 3,000,000 IU per 1 suppository 2 times a day after 12 hours daily for 10 days, then 3 times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

Children under the age of 6 months are recommended 300,000-500,000 IU per day; At the age of 6 to 12 months - 500,000 IU per day.

Children aged 1 to 7 years recommended 3,000,000 IU per 1 m2 body surface area per day.

Children over 7 years are recommended 5000000 IU per 1 m2 body surface area per day.

The drug is used 2 times a day after 12 h first 10 days daily, then 3 times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

Calculation of the daily dose of the drug for each patient is made by multiplying the dose recommended for a given age by the body surface area, calculated from the nomogram to calculate the surface area of the body in terms of height and weight according to Garford, Terry and Rourke. Calculation of a single dose is carried out by dividing the calculated daily dose by 2 administrations, the resulting value is rounded to a higher dosage of the suppository.

In chronic viral hepatitis of marked activity and cirrhosis of the liver, prior to plasmapheresis and / or hemosorption, children under the age of 7 years are recommended to receive VFERHONON® 150000 IU, children over the age of 7 years, VIFERON® 500,000 IU per 1 suppository 2 times a day every 12 hours daily Within 14 days.

Infectious and inflammatory diseases of the urogenital tract (chlamydia, CMV infection, ureaplasmosis, trichomoniasis, gardnerellez, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults, including pregnant women, as part of complex therapy. The recommended dose for adults is VIFERON® 500,000 IU at 1 suppository 2 times a day after 12 hours daily for 5-10 days. According to clinical indications, therapy can be continued.

Pregnant from the second trimester of pregnancy (starting from 14 weeks gestation) recommended VIFERON® 500,000 IU for 1 suppository 2 times a day after 12 hours daily for 10 days, then for 9 days 3 times with an interval of 3 days (on the 4th Day) 1 suppository 2 times a day after 12 hours. Then every 4 weeks before the delivery of VIFERON® 150000 IU for 1 suppository 2 times a day after 12 hours daily for 5 days. If necessary, it is shown before delivery (from 38 weeks gestation) VIFERON® 500,000 IU per 1 suppository 2 times a day after 12 hours daily for 10 days.

Primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate-to-moderate course, incl. Urogenital form in adults, including pregnant women. The recommended dose for adults is VIFERON® 1,000,000 IU at 1 suppository 2 times a day at 12 hours daily for 10 days or more with a recurrent infection. According to clinical indications, therapy can be continued. It is recommended to start treatment immediately after the appearance of the first signs of skin and mucous membrane lesions (itching, burning, redness). In the treatment of recurrent herpes it is desirable to begin treatment in the prodromal period or at the very beginning of the manifestation of signs of relapse.

Pregnant from the second trimester of pregnancy (starting from 14 weeks gestation) recommended VIFERON® 500,000 IU for 1 suppository 2 times a day after 12 hours daily for 10 days, then for 9 days 3 times with an interval of 3 days (on the 4th Day) 1 suppository 2 times a day after 12 hours. Then every 4 weeks before the delivery of VIFERON® 150000 IU for 1 suppository 2 times a day after 12 hours daily for 5 days. If necessary, it is shown before delivery (from 38 weeks gestation) VIFERON® 500,000 IU per 1 suppository 2 times a day after 12 hours daily for 10 days.

Special instructions

Ointment. Open the tube stored in the refrigerator for 1 month.

Gel. The opened tube should not be stored in the refrigerator for more than 2 months.

Age restrictions for the use of the gel are absent.

Release Form

Ointment for local and external use. For 12 g in tubes of aluminum. 1 tube in a pack of cardboard.

Gel for external and topical application. For 12 g in tubes of aluminum. 1 tube in a pack of cardboard.

Suppositories for rectal administration. For 5 or 10 suppositories in a PVC / PVC contour cell pack. 1 contour cell pack of 10 suppositories or 2 contourcell packs of 5 suppositories in a pack of cardboard.

Manufacturer

OOO FERON (Russia).

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Viferon

In a dry, the dark place at a temperature of 2-8 ° C.

Keep out of the reach of children.

Shelf life of the drug Viferon

Gel for local and external application 36000 IU / g - 1 year.

Ointment for topical and topical application 40000 IU / g - 1 year.

Suppositories rectal 150000 IU - 2 years.

Suppositories rectal 500000 IU - 2 years.

Suppositories rectal 1000000 IU - 2 years.

Suppositories rectal 3,000,000 IU - 2 years.

Do not use after the expiry date printed on the package.

Someone from the USA - just purchased the goods:
Chelohart 60 capsules